1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. AC Immune SA
  6. Summary
    ACIU   CH0329023102

AC IMMUNE SA

(ACIU)
  Report
Delayed Nasdaq  -  05/20 04:00:01 pm EDT
3.150 USD   +0.96%
05/17AC Immune CEO Andrea Pfeifer Receives Aenne Burda Award
AQ
05/10AC Immune's Anti-Abeta Vaccine Results From Phase 1b Study In Down Syndrome Published In JAMA Neurology
AQ
05/09AC Immune Says Anti-Abeta Vaccine Found to be Safe in Adult Patients With Down Syndrome
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Nasdaq
05/17/2022 05/18/2022 05/19/2022 05/20/2022 Date
3.1(c) 3.2(c) 3.12(c) 3.15(c) 3.15 Last
58 388 168 783 354 420 101 711 101 711 Volume
+3.68% +3.23% -2.50% +0.96% +0.96% Change
More quotes
Estimated financial data (e)
Sales 2022 2,40 M 2,47 M 2,47 M
Net income 2022 -79,6 M -82,0 M -82,0 M
Net Debt 2022 - - -
P/E ratio 2022 -3,18x
Yield 2022 -
Sales 2023 55,0 M 56,6 M 56,6 M
Net income 2023 -28,1 M -28,9 M -28,9 M
Net Debt 2023 - - -
P/E ratio 2023 -9,45x
Yield 2023 -
Capitalization 234 M 241 M 241 M
Capi. / Sales 2022 97,6x
Capi. / Sales 2023 4,26x
Nbr of Employees -
Free-Float 44,6%
More Financials
Company
AC Immune SA is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on precision medicine for neurodegenerative diseases. It designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines... 
More about the company
Ratings of AC Immune SA
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
C
More Ratings
All news about AC IMMUNE SA
05/17AC Immune CEO Andrea Pfeifer Receives Aenne Burda Award
AQ
05/10AC Immune's Anti-Abeta Vaccine Results From Phase 1b Study In Down Syndrome Published I..
AQ
05/09AC Immune Says Anti-Abeta Vaccine Found to be Safe in Adult Patients With Down Syndrome
MT
05/09AC Immune's Anti-Abeta Vaccine Results from Phase 1b Study in Down Syndrome Published i..
AQ
05/09AC Immune SA's Anti-Abeta Vaccine Results from Phase 1b Study in Down Syndrome Publishe..
CI
04/28AC IMMUNE : Condensed Consolidated Balance Sheets (Unaudited) - Form 6-K
PU
04/28AC IMMUNE : Q1 Earnings Snapshot
AQ
04/28AC Immune SA Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
04/28AC Immune Reports First Quarter 2022 Financial Results and Provides Corporate Update
AQ
04/27AC Immune to Present at the B. Riley Annual Neuro & Ophthalmology Virtual Investor Conf..
AQ
04/08AC Immune Appoints Chief Human Resource Officer, Interim CFO
MT
04/08AC IMMUNE : Reports Changes to Senior Management - Form 6-K
PU
04/08Joerg Hornstein to join Lundbeck as Chief Financial Officer and Head of Corporate Funct..
AQ
04/08AC Immune SA Announces Senior Management Changes
CI
04/08AC Immune SA Announces Executive Changes
CI
More news
News in other languages on AC IMMUNE SA
05/09AC Immune affirme que le vaccin anti-Abeta s'est avéré sûr chez les patients adultes at..
05/09Les résultats du vaccin anti-Abêta d'AC Immune SA issus de l'étude de phase 1b dans le ..
04/28AC Immune SA annonce ses résultats pour le premier trimestre clos le 31 mars 2022
04/08AC Immune nomme un directeur des ressources humaines et un directeur financier intérima..
04/08AC Immune SA annonce des changements de direction
More news
Analyst Recommendations on AC IMMUNE SA
More recommendations
Chart AC IMMUNE SA
Duration : Period :
AC Immune SA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AC IMMUNE SA
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 3,03 CHF
Average target price 12,66 CHF
Spread / Average Target 318%
EPS Revisions
Managers and Directors
Andrea Pfeifer Chief Executive Officer & Director
J÷rg Hornstein Chief Financial Officer
Douglas E. Williams Chairman
Marie Kosco-Vilbois Chief Scientific Officer
Piergiorgio Donati Chief Technical Operations Officer
Sector and Competitors
1st jan.Capi. (M$)
AC IMMUNE SA-36.97%241
MODERNA, INC.-43.55%57 031
LONZA GROUP AG-29.91%40 761
IQVIA HOLDINGS INC.-28.50%38 185
SEAGEN INC.-7.74%26 255
ICON PUBLIC LIMITED COMPANY-30.82%17 418